Tuberc Respir Dis > Volume 62(2); 2007 > Article
Tuberculosis and Respiratory Diseases 2007;62(2):134-139.
DOI:    Published online February 1, 2007.
Gefitinib-Related Interstitial Pneumonia.
Ho Jin Lee, Seung Bum Nam, Jae Wook Jung, Im Il Na, Cheol Hyeon Kim, Baek Yeol Ryoo, Du Whan Choe, Jin Hyung Kang, Jae Cheol Lee
1Department of Internal Medicine, Korea Cancer Center Hospital, Korea.
2Department of Radiology, Korea Cancer Center Hospital, Korea.
3Department of Internal Medicine, Kangnam St. Mary's Hospital, Seoul, Korea.
Gefitinib is a novel drug used to treat advanced non-small cell lung cancer. However, drug-related interstitial pneumonia is a major life-threatening side effect, which has a worldwide prevalence of 0.3-0.4%. In Japan, the prevalence is high as 3-4% but the actual frequency in Korea has not been officially assessed. We report two cases of gefitinib-induced interstitial lung disease during the treatment of non-small cell lung cancer. High-resolution computerized tomography (HRCT) of one case showed nonspecific ground glass opacity and the chest x-ray of another case showed diffuse bilateral ground glass opacity. The former patient showed a rapid good response to corticosteroid treatment whereas the latter died despite receiving aggressive treatment with high dose corticosteroid and empirical antibiotics.
Key Words: Gefitinib, Non-small cell lung cancer, Interstitial pneumonia

Article category

Browse all articles >


Browse all articles >

Editorial Office
101-605, 58, Banpo-daero, Seocho-gu (Seocho-dong, Seocho Art-Xi), Seoul 06652, Korea
Tel: +82-2-575-3825, +82-2-576-5347    Fax: +82-2-572-6683    E-mail:                

Copyright © 2023 by The Korean Academy of Tuberculosis and Respiratory Diseases. All rights reserved.

Developed in M2PI

Close layer
prev next